Bath Savings Trust Co Sells 80 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Bath Savings Trust Co lowered its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.6% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 13,622 shares of the medical equipment provider’s stock after selling 80 shares during the period. Bath Savings Trust Co’s holdings in Intuitive Surgical were worth $6,692,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Intuitive Surgical by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after purchasing an additional 493,126 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Intuitive Surgical by 1.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock valued at $5,726,102,000 after buying an additional 272,741 shares in the last quarter. Capital World Investors boosted its stake in shares of Intuitive Surgical by 1.0% in the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock valued at $2,907,079,000 after buying an additional 73,634 shares during the period. Jennison Associates LLC grew its position in Intuitive Surgical by 4.6% during the first quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock worth $1,791,253,000 after buying an additional 198,483 shares in the last quarter. Finally, Fisher Asset Management LLC increased its stake in Intuitive Surgical by 1.9% during the 4th quarter. Fisher Asset Management LLC now owns 4,488,048 shares of the medical equipment provider’s stock worth $1,514,088,000 after acquiring an additional 82,652 shares during the period. 83.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on ISRG. Morgan Stanley boosted their price target on Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Piper Sandler boosted their target price on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Truist Financial increased their price target on shares of Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Stifel Nicolaus boosted their price objective on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research report on Friday, July 19th. Finally, Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their target price for the company from $380.00 to $510.00 in a report on Friday, August 2nd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and an average price target of $449.70.

Insider Buying and Selling

In other Intuitive Surgical news, Director Amy L. Ladd sold 450 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the sale, the director now owns 821 shares of the company’s stock, valued at approximately $402,519.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Intuitive Surgical news, Director Amy L. Ladd sold 450 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the transaction, the director now owns 821 shares in the company, valued at approximately $402,519.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 53,120 shares of company stock valued at $25,528,753. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Stock Down 2.2 %

NASDAQ:ISRG opened at $471.23 on Tuesday. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $496.48. The company has a fifty day moving average of $476.55 and a 200-day moving average of $432.12. The firm has a market capitalization of $167.15 billion, a P/E ratio of 85.06, a P/E/G ratio of 5.39 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. The firm had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business’s revenue was up 14.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.18 earnings per share. On average, analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.